Telitacicept

Cat. No.:	HY-P99568
CAS No.:	2136630-26-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease[1].
IC_{50} & Target	(BLyS)/APRIL[1]
In Vivo	Telitacicept (15 and 7.5mpk, i.p.) improves mouse experimental autoimmune encephalomyelitis (EAE) clinical symptoms in MOG_{35-55} induced EAE model mice[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MOG_{35-55} peptide-induced EAE mice model (6- to 8-week-old, female)[2]
Dosage:	15mpk and 7.5mpk
Administration:	i.p.
Result:	Reduced the severity of tail paralyses and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927). Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.

REFERENCES

[1]. Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021 Apr 1;159:105704.

[2]. Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences. March 31, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA